0.09
-0.0228(-19.37%)
Currency In USD
| Previous Close | 0.12 |
| Open | 0.11 |
| Day High | 0.11 |
| Day Low | 0.06 |
| 52-Week High | 0.52 |
| 52-Week Low | 0.03 |
| Volume | 2.31M |
| Average Volume | 1.12M |
| Market Cap | 6.52M |
| PE | -0.31 |
| EPS | -0.31 |
| Moving Average 50 Days | 0.12 |
| Moving Average 200 Days | 0.23 |
| Change | -0.02 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $0.78 as of April 27, 2025 at a share price of $0.095. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $49.95 as of April 27, 2025 at a share price of $0.095.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
GlobeNewswire Inc.
Apr 07, 2025 5:26 PM GMT
OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders an
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
GlobeNewswire Inc.
Apr 04, 2025 8:45 PM GMT
OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Mar 27, 2025 12:05 PM GMT
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant v
Data not available